发布求助
文献互助 智能选刊 最新文献

NeuroPharmac Journal最新文献

筛选
英文 中文
Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19) 目前超说明书药物治疗在新型冠状病毒病(COVID-19)治疗中的应用
NeuroPharmac Journal Pub Date : 2020-03-30 DOI: 10.37881/1.511
A. Pathan
{"title":"Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19)","authors":"A. Pathan","doi":"10.37881/1.511","DOIUrl":"https://doi.org/10.37881/1.511","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, Severe acute respiratory syndrome SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. There are no FDA- approved therapeutics or drugs to treat, cure or prevent COVID-19. Some reported case studies indicated the significance of Chloroquine use in mild cases and Lopinavir and Ritonavir in severe cases of COVID-19 respectively. Indian Council of Medical Research, India issued a protocol which is to be implemented along with the WHO guidelines on clinical management of mild and severe acute respiratory infection when COVID-19 infection is suspected in Indian patients as a restricted public health emergency use.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114213240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Siponimod: A new approved oral drug to treat multiple sclerosis 西ponimod:一种新的口服药物，用于治疗多发性硬化症
NeuroPharmac Journal Pub Date : 2019-08-25 DOI: 10.37881/1.421
A. Pathan
{"title":"Siponimod: A new approved oral drug to treat multiple sclerosis","authors":"A. Pathan","doi":"10.37881/1.421","DOIUrl":"https://doi.org/10.37881/1.421","url":null,"abstract":"The U.S. Food and Drug Administration on 26 March 2019 approved Siponimod tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The efficacy of Siponimod was shown in a clinical trial of 1,651 patients that compared Siponimod to placebo in patients with Secondary Progressive Multiple Sclerosis (SPMS) who had evidence of disability progression in the prior two years and no relapses in the three months prior to enrollment. The primary endpoint of the study was the time to three-month confirmed progression in disability. The fraction of patients with confirmed progression of disability was statistically significantly lower in the Siponimod group than in the placebo group. Siponimod also decreased the number of relapses experienced by these patients. In the subgroup of patients with non-active SPMS, the results were not statistically significant.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124859254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease isstradefylline:一种新的附加药物，用于治疗成人帕金森病的发作
NeuroPharmac Journal Pub Date : 2019-08-25 DOI: 10.37881/1.422
A. Pathan
{"title":"Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease","authors":"A. Pathan","doi":"10.37881/1.422","DOIUrl":"https://doi.org/10.37881/1.422","url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127145478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review 大麻二酚:FDA批准用于lenox - gastaut综合征和Dravet综合征的新药:药物治疗回顾
NeuroPharmac Journal Pub Date : 2019-04-25 DOI: 10.37881/1.413
A. Pathan
{"title":"Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review","authors":"A. Pathan","doi":"10.37881/1.413","DOIUrl":"https://doi.org/10.37881/1.413","url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129759212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura Caplacizumab: 2019年fda批准的首个治疗成人获得性血栓性血小板减少性紫癜的药物
NeuroPharmac Journal Pub Date : 2019-04-25 DOI: 10.37881/1.414
Feras Almarshad
{"title":"Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura","authors":"Feras Almarshad","doi":"10.37881/1.414","DOIUrl":"https://doi.org/10.37881/1.414","url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125137300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autism Spectrum Disorder: Medications overview 自闭症谱系障碍:药物概述
NeuroPharmac Journal Pub Date : 2019-04-25 DOI: 10.37881/1.411
A. Pathan, Feras Almarshad
{"title":"Autism Spectrum Disorder: Medications overview","authors":"A. Pathan, Feras Almarshad","doi":"10.37881/1.411","DOIUrl":"https://doi.org/10.37881/1.411","url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117082471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome fda于2018年批准首个治疗与Dravet综合征相关的癫痫发作的疗法
NeuroPharmac Journal Pub Date : 2019-04-25 DOI: 10.37881/1.412
A. Pathan, A. Alshahrani
{"title":"FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome","authors":"A. Pathan, A. Alshahrani","doi":"10.37881/1.412","DOIUrl":"https://doi.org/10.37881/1.412","url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"2013 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121320406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review 斯特里彭托尔:新批准的用于治疗德拉韦综合征的药物:药物治疗学综述
NeuroPharmac Journal Pub Date : 2019-04-25 DOI: 10.37881/1.415
A. Pathan
{"title":"Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review","authors":"A. Pathan","doi":"10.37881/1.415","DOIUrl":"https://doi.org/10.37881/1.415","url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132286414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Possible management of non-motor symptoms of Parkinson’s Disease 帕金森病非运动症状的可能治疗方法
NeuroPharmac Journal Pub Date : 2018-12-25 DOI: 10.37881/1.332
A. Pathan, A. Alshahrani
{"title":"Possible management of non-motor symptoms of Parkinson’s Disease","authors":"A. Pathan, A. Alshahrani","doi":"10.37881/1.332","DOIUrl":"https://doi.org/10.37881/1.332","url":null,"abstract":"Parkinson's disease (PD) is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed but not halted, by treatment. The goal of the medical management of Parkinson's disease is to provide control of signs and symptoms for as long as possible while minimizing adverse effects. Parkinson’s disease (PD) is classically considered as a motor disease, with tremor, rigidity, bradykinesia and gait problems as the classic motor features. However, non-motor manifestations (NMM) of PD have become increasingly recognized – they can often be more disabling than the motor symptoms. Non-motor manifestations of PD result from neuronal degeneration in widespread areas of the brainstem. Unfortunately, NMM is often underrecognized, and therefore, undertreated. The goal of this article is to provide a guide to recognizing and managing these NMM so that quality of life of the patient with PD can improve.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"54 16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125533740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gold Standard of Symptomatic treatment in Parkinson disease: Carbidopa / Levodopa 帕金森病对症治疗的金标准:卡比多巴/左旋多巴
NeuroPharmac Journal Pub Date : 2018-12-25 DOI: 10.37881/1.331
A. Pathan, A. Alshahrani
{"title":"Gold Standard of Symptomatic treatment in Parkinson disease: Carbidopa / Levodopa","authors":"A. Pathan, A. Alshahrani","doi":"10.37881/1.331","DOIUrl":"https://doi.org/10.37881/1.331","url":null,"abstract":"Parkinson's disease (PD) is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed but not halted, by treatment. The goal of the medical management of Parkinson's disease is to provide control of signs and symptoms for as long as possible while minimizing adverse effects. Levodopa coupled with a peripheral decarboxylase inhibitor (PDI), such as carbidopa, remains the gold standard of symptomatic treatment of motor features of Parkinson's disease. It provides the greatest antiparkinsonian benefit with the fewest adverse effects in the short term. However, its long-term use is associated with the development of fluctuations and dyskinesias. This review article is written to summarize the clinical and pharmacological data of carbidopa and levodopa which will be helpful to neurologists and physicians.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115023740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信